Time-dependent pharmacodynamic effects of phenobarbital in humans.
The relationship between the serum concentration of phenobarbital and its pharmacodynamic effects was assessed in a double-blind controlled study in eight normal volunteers who were given single oral doses of phenobarbital (200 mg) and placebo according to a randomized cross-over design. Compared with the placebo session, phenobarbital was found to induced CNS-depressing effects as assessed by visual analogue rating scales (VARS) and critical flicker fusion tests (CFF), whereas no significant effects were detected on choice reaction times, tappings, and digit symbol substitutions. There was a clear-cut dissociation between the time course of serum phenobarbital levels, which remained at a plateau throughout most of the period of observation (up to 72 h) and its subjective (VARS) and objective (CFF) effects, which could be documented only for up to 9 h after administration. These data suggest that pharmacodynamic tolerance develops rapidly even after a single oral dose of the drug. Multiple Sleep Latency Tests (MSLTs) were also performed in the same subjects and showed that phenobarbital increases diurnal drowsiness and attenuates the circadian variation in drowsy state that is seen under control conditions. MLSTs appeared to be superior to other tests in documenting the sedative effects of the barbiturate.
Barzaghi
N
N
Department of Internal Medicine, University of Pavia, Italy.
Gatti
G
G
Manni
R
R
Galimberti
C A
CA
Zucca
C
C
Tartara
A
A
Perucca
E
E
D000328:Adult; D006801:Humans; D006993:Hypnotics and Sedatives; D008297:Male; D010634:Phenobarbital / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology*; D011597:Psychomotor Performance / Q000187:drug effects; D012890:Sleep / Q000187:drug effects; D013997:Time Factors
D006993:Hypnotics and Sedatives; D010634:Phenobarbital